Overview

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

Status:
Completed

Trial end date:
2019-01-03

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess safety, tolerability of the different vaccine schedules (different regimen durations and different number of dose administrations) with Ad26.Mos.HIV and Clade C Glycoprotein (gp) 140 and to assess Envelope (Env)-binding Antibody (Ab) responses of the different vaccine schedules.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Vaccines & Prevention B.V.

Treatments:

Aluminum phosphate
Krestin
Vaccines